PriceTargets.com logo

SpringWorks Therapeutics - SWTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $51.80
  • Forecasted Upside: 75.71%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$29.48 As of 12/5/2023 11:46 AM ET
▼ -2.18 (-6.89%)

This chart shows the closing price for SWTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SpringWorks Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SWTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SWTX

Analyst Price Target is $51.80
▲ +75.71% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for SpringWorks Therapeutics in the last 3 months. The average price target is $51.80, with a high forecast of $64.00 and a low forecast of $41.00. The average price target represents a 75.71% upside from the last price of $29.48.

This chart shows the closing price for SWTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in SpringWorks Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$47.00 ➝ $52.00Low
11/28/2023HC WainwrightBoost TargetBuy ➝ Buy$52.00 ➝ $64.00Low
11/20/2023HC WainwrightLower TargetBuy ➝ Buy$58.00 ➝ $52.00Low
11/16/2023WedbushReiterated RatingOutperform$45.00Low
11/9/2023HC WainwrightLower TargetBuy ➝ Buy$66.00 ➝ $58.00Low
11/2/2023WedbushReiterated RatingOutperform$45.00Low
8/24/2023HC WainwrightReiterated RatingBuy ➝ Buy$66.00Low
8/7/2023HC WainwrightLower TargetBuy ➝ Buy$105.00 ➝ $66.00Low
7/20/2023The Goldman Sachs GroupBoost TargetBuy$43.00 ➝ $49.00Low
4/28/2023BarclaysLower Target$55.00 ➝ $41.00Low
4/20/2023HC WainwrightReiterated RatingBuy$105.00Low
3/7/2023JPMorgan Chase & Co.Boost TargetOverweight$53.00 ➝ $57.00Low
3/7/2023HC WainwrightBoost TargetBuy$99.00 ➝ $105.00Low
1/26/2023The Goldman Sachs GroupBoost TargetBuy$40.00 ➝ $45.00Low
12/1/2022Bank of AmericaInitiated CoverageBuy$45.00Low
11/24/2022WedbushSet Target$45.00Low
11/4/2022HC WainwrightLower TargetBuy$103.00 ➝ $99.00Low
10/21/2022The Goldman Sachs GroupLower TargetBuy$51.00 ➝ $44.00Low
9/12/2022HC WainwrightBoost TargetBuy$94.00 ➝ $103.00Low
8/9/2022HC WainwrightLower TargetBuy$95.00 ➝ $94.00Low
6/20/2022WedbushSet Target$53.00Low
6/6/2022HC WainwrightLower TargetBuy$142.00 ➝ $95.00Low
5/27/2022WedbushLower TargetOutperform$110.00 ➝ $50.00High
5/24/2022The Goldman Sachs GroupLower TargetBuy$92.00 ➝ $76.00High
3/1/2022HC WainwrightBoost Target$137.00 ➝ $142.00High
9/8/2021JPMorgan Chase & Co.Boost TargetOverweight$97.00 ➝ $105.00Medium
8/5/2021HC WainwrightBoost TargetBuy$136.00 ➝ $137.00Low
7/21/2021HC WainwrightReiterated RatingBuy$124.00 ➝ $136.00Low
7/20/2021The Goldman Sachs GroupBoost TargetBuy$107.00 ➝ $123.00High
3/22/2021The Goldman Sachs GroupReiterated RatingBuy$112.00N/A
2/26/2021BarclaysBoost TargetOverweight$92.00 ➝ $105.00High
2/25/2021HC WainwrightBoost TargetBuy$101.00 ➝ $124.00High
1/22/2021BarclaysBoost TargetOverweight$83.00 ➝ $92.00High
1/19/2021HC WainwrightBoost TargetBuy$87.00 ➝ $101.00Low
12/28/2020HC WainwrightReiterated RatingBuy$73.00 ➝ $87.00N/A
12/17/2020JPMorgan Chase & Co.Boost Target$57.00 ➝ $85.00High
12/17/2020BarclaysBoost TargetPositive ➝ Overweight$70.00 ➝ $83.00Medium
10/29/2020HC WainwrightBoost TargetBuy$58.00 ➝ $73.00Medium
9/15/2020BarclaysBoost TargetOverweight$52.00 ➝ $55.00Low
8/17/2020WedbushReiterated RatingBuyHigh
8/13/2020BarclaysReiterated RatingBuyHigh
8/13/2020WedbushBoost TargetOutperform$48.00 ➝ $50.00High
8/6/2020HC WainwrightReiterated RatingBuy$58.00Medium
7/22/2020HC WainwrightReiterated RatingBuy$58.00High
7/14/2020HC WainwrightReiterated RatingBuy$58.00High
6/23/2020HC WainwrightReiterated RatingBuy$58.00Medium
5/13/2020WedbushBoost TargetOutperform$45.00 ➝ $48.00Medium
5/5/2020BarclaysInitiated CoverageOverweight$48.00Low
4/28/2020HC WainwrightReiterated RatingBuy$58.00High
4/14/2020HC WainwrightLower TargetBuy$60.00 ➝ $58.00High
3/19/2020HC WainwrightUpgradeNeutral ➝ BuyHigh
3/4/2020HC WainwrightDowngradeBuy ➝ Neutral$40.00High
2/3/2020HC WainwrightReiterated RatingBuy$40.00High
1/21/2020HC WainwrightReiterated RatingBuy$34.00 ➝ $40.00Low
1/13/2020CowenReiterated RatingBuyMedium
12/17/2019HC WainwrightReiterated RatingBuy$34.00High
12/10/2019HC WainwrightReiterated RatingBuy$34.00Low
12/4/2019HC WainwrightInitiated CoverageBuy$33.00High
10/8/2019The Goldman Sachs GroupInitiated CoverageBuy$37.00Medium
10/8/2019JPMorgan Chase & Co.Initiated CoverageOverweight$32.00Medium
10/8/2019CowenInitiated CoverageOutperformMedium
10/8/2019WedbushInitiated CoverageOutperform$33.00Medium
(Data available from 12/5/2018 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
6/8/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2023
  • 6 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2023
  • 8 very positive mentions
  • 20 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
Mentions as of
12/5/2023

Current Sentiment

  • 8 very positive mentions
  • 20 positive mentions
  • 4 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

SpringWorks Therapeutics logo
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More

Today's Range

Now: $29.48
Low: $28.46
High: $29.51

50 Day Range

MA: $23.16
Low: $18.94
High: $31.90

52 Week Range

Now: $29.48
Low: $18.00
High: $34.16

Volume

2,358,268 shs

Average Volume

709,521 shs

Market Capitalization

$1.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of SpringWorks Therapeutics?

The following Wall Street research analysts have issued research reports on SpringWorks Therapeutics in the last year: Barclays PLC, HC Wainwright, JPMorgan Chase & Co., The Goldman Sachs Group, Inc., and Wedbush.
View the latest analyst ratings for SWTX.

What is the current price target for SpringWorks Therapeutics?

5 Wall Street analysts have set twelve-month price targets for SpringWorks Therapeutics in the last year. Their average twelve-month price target is $51.80, suggesting a possible upside of 75.7%. HC Wainwright has the highest price target set, predicting SWTX will reach $64.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $41.00 for SpringWorks Therapeutics in the next year.
View the latest price targets for SWTX.

What is the current consensus analyst rating for SpringWorks Therapeutics?

SpringWorks Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SWTX will outperform the market and that investors should add to their positions of SpringWorks Therapeutics.
View the latest ratings for SWTX.

What other companies compete with SpringWorks Therapeutics?

Other companies that are similar to SpringWorks Therapeutics include Vir Biotechnology, Kymera Therapeutics, BioCryst Pharmaceuticals, Recursion Pharmaceuticals and Relay Therapeutics. Learn More about companies similar to SpringWorks Therapeutics.

How do I contact SpringWorks Therapeutics' investor relations team?

SpringWorks Therapeutics' physical mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The company's listed phone number is 203-883-9490 and its investor relations email address is [email protected]. The official website for SpringWorks Therapeutics is www.springworkstx.com. Learn More about contacing SpringWorks Therapeutics investor relations.